Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin and/or Greater Occipital Nerve Block for Chronic Migraine
NCT07535723Not yet recruiting
- Sponsor
- Beni Suef University
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of botulinum toxin type A in chronic migraine (3 arms), sponsored by Beni Suef University. Primary endpoint: Proportion of participants achieving ≥50% reduction in monthly migraine days at 3 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT07535723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535723.